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Aim: In 2008, the Danish National Chronic Lymphocytic Leukemia Registry was founded 
within the Danish National Hematology Database. The primary aim of the registry is to assure 
quality of diagnosis and care of patients with chronic lymphocytic leukemia (CLL) in  Denmark. 
Secondarily, to evaluate adherence to national guidelines and to provide source data for research 
purposes.
Study population: All patients diagnosed with CLL in Denmark from 2008 onward are included 
in the registry. Patients are followed in one of nine hematology centers. All centers participate 
in the registry and are all obliged to collect data.
Main variables: Predefined data are collected at the time of diagnosis, and follow-up at the time 
of significant events: treatment, progression, transplantation, and death. Parameters included 
in the International Workshop on Chronic Lymphocytic Leukaemia criteria for diagnosis, and 
for decision on treatment initiation as well as characteristics included in the CLL International 
Prognostic Index are collected.
Descriptive data: To ensure full coverage of Danish CLL patients in the registry, both con-
tinuous queries in case of missing data, and cross-referencing with the Danish National Patient 
Registry are performed. Data from the registry are published in an annual report summarizing 
the collected data, the overall survival for yearly cohorts, and the degree of data coverage. Per 
year approximately 450 new patients with CLL are registered in the registry, cumulative as of 
July 1, 2015, 3,082 patients have been registered.
Conclusion: The Danish National CLL Registry is based within the Danish National Hema-
tology Database. The registry covers a cohort of all patients diagnosed with CLL in Denmark 
since 2008. It forms the basis for quality assessment of CLL treatment in Denmark and offers 
a unique opportunity for population-based research.
Keywords: CLL, population based, epidemiology, targeted treatment, survival, comorbidity
Background
In Denmark, a number of regional and national quality databases, based on individual 
patient data, have been established. The Danish National Hematology Database was 
founded in 2005 by a fusion of The Danish National Lymphoma Registry, The Danish 
National Acute Leukemia Registry, and The Danish National Myeloma Database. In 
2008, The Danish National Chronic Lymphocytic Leukemia Registry was founded 
within the Danish National Hematology Database. The overall purpose of the registry 
is to assure high quality patient care and diagnostics for patients with chronic lympho-
cytic leukemia (CLL) in Denmark, to assess adherence to national guidelines for CLL, 
and to provide source data for research purposes. The Danish National CLL Registry 
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is approved by the National Board of Health. Based on the 
Danish legislation, these nationwide registries are exempt 
from the requirement to achieve informed consent from the 
individual patients enrolled. If the data are subsequently used 
for research purposes, approval from the Data Protection 
Agency or the ethics committee system is required, depend-
ing on the project.
Study population
All patients diagnosed with CLL in Denmark from 2008 
onward are included in the registry. Per year approximately 
450 new patients with CLL are registered in the registry, 
cumulative as of July 1, 2015, 3,082 patients have been regis-
tered, no retrospective registration of patients diagnosed prior 
to 2008 has been performed. All patients are initially followed 
in one of nine hematology centers in Denmark (see Figure 1 
for data flowchart). Patients needing treatment and close 
monitoring are continuously followed in one of the centers, 
a minority of patients with low risk disease are followed by 
their general practitioner after initial diagnosis at one of the 
hematology centers. All nine centers participate in the regis-
try and are obliged to collect data on all newly diagnosed 
patients with CLL. The registry is owned by the Danish 
Regions (five local government entities),1 with centrali zed 
data management through the Danish  Multidisciplinary 
Cancer Groups.2 The database is supported by the Registry 
Support Centre of Epidemiology and Biostatistics (East) and 
the Registry Support Centre of Clinical Quality and Health 
Informatics (East).
Main variables
A range of predefined variables are collected at the time 
of diagnosis. These include baseline demographic charac-
teristics, prognostic markers, clinical stage, World Health 
 Organization performance status,3 and patient-reported 
symptoms. Dates and results of prognostic tests and events are 
registered to allow for follow-up over time at the individual 
patient level (Table 1). Continuous collection of follow-up 
data in the registry is carried out according to a predefined 
range of variables at the time of significant events: treatment, 
progression, transplantation or death. All variables included 
in the International Workshop on Chronic Lymphocytic 
Leukaemia (IWCLL) criteria4 for diagnosis and treatment 
initiation as well as the characteristics included in the Inter-
national Prognostic Index for Patients with CLL (CLL-IPI)5 
are included in the registry (Table 1).
Information on administrative 
issues
Funding for the Danish National CLL Registry within the 
Danish National Hematology Database is achieved through 
a yearly application to the Danish Regions’ Database Funds 
for The Danish Clinical Registries,1 which is funded by the 
Danish Regions. The Danish health system is also  supported 
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Figure 1 Data flowchart.
Notes: Dataflow in The Danish National CLL Registry. At the time of diagnosis, baseline registration is performed at one of nine centers. Data are validated through cross-
referencing with The National Patient Registry (NPR) and The Danish Cancer Registry (DCR). Data describing follow-up variables are continuously registered at the time 
of significant events. These data form the basis for quality assessment of treatment for patients with CLL in Denmark and offers a unique opportunity for population-based 
research.
Abbreviation: CLL, chronic lymphocytic leukemia.
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by a number of nationwide registries; The National Patient 
Registry,6 The Danish Cancer Registry,7 the Danish National 
Pathology Registry and Data Bank,8 and the Cause of death 
register.9 To ensure full coverage of the Danish CLL cohort in 
the Danish National CLL Registry, regular cross-referencing 
with The National Patient Registry is performed. As this 
regis try forms the economic basis for all hospital departments 
in Denmark and no patients can be admitted to an inpatient 
or outpatient specialist clinic in Denmark without being 
regis tered, complete coverage of a national cohort of patients 
with CLL is assured. Additionally, The Danish Cancer Reg-
istry and the Danish National Pathology Registry and Data 
Bank are cross-referenced to assure complete data coverage. 
The coverage of the registry is reported in yearly reports at 
lymphoma.dk. For the years 2011–2013, 99% coverage was 
achieved; for 2014, 96% coverage was achieved due to a 
few cases not yet entered into the database.10 The data are 
validated through the entry process and relevant patients 
are included in follow-up query lists. To assure high quality 
of data and consistent follow-up, queries based on cross-
referencing with the mentioned registries identify patients 
who have received treatment for any malignancy or have died 
since the last follow-up (see Figure 1 for data flowchart). The 
completeness of data entry for patients receiving treatment 
is reported in the yearly reports. For the years 2011–2014, 
Registry/
epidemiological
Clinical
trials
Annual
reports
Translational
The Danish
National
CLL
RegistryBiobank
Figure 2 Research strategy/potential.
Notes: The data registered in The Danish National CLL Registry can be used 
to address research questions at a population-based level through registry-based 
epidemiological studies, translational research using biobank samples, and by 
providing easy access to high quality long-term follow-up data for ongoing clinical 
trials.
Abbreviation: CLL, chronic lymphocytic leukemia.
Table 1 Main variables
Variable name Baseline (B) 
Follow-up (F)
IWCLL (I) 
CLL-IPI 
(C)
Demographics
ID B
Sex B
Date of birth B
Age B C
Family history of CLL B
Date of diagnostic test B
Diagnostics and results
Bone marrow biopsy B
Absolute lymphocyte count B I
Flow cytometry B I
FISH (del 11q, trisomy 12, del 13q14,  
del 17p)
B I, C
IGHV mutational status B I, C
Imaging B
Symptoms and clinical observations
weight loss (.10%/6 months) B
Fever of unknown origin (.2 weeks) B
Fatigue B
Night sweat B
Performance status wHO B
Binet/Rai B I, C
Prognostic tests and results
IGHV mutational status ($98%) B
ZAP 70 B
CD38 positive B
Beta 2 microglobulin .340 nmol/.4 mg B C
Lymphocyte doubling time ,12 months B
Anemia (Hb ,6.2 mmol/L)/ 
thrombocytopenia (,100 mia/L)
B
Massive-progressive lymphadenopathy/
splenomegaly
B
Increasing lymphocytosis (.50%/2 months) B
Rapid lymphocyte doubling time  
(,6 months)
B
Follow-up/treatment
Chemotherapy regimen F
Immune therapy F
Date of treatment start F
Date treatment end F
Response F
Date of transplantation (if applicable) F
MRD analysis performed F
Date of progression/relapse F
New FISH result (if applicable) F
End of follow-up
Date of death (if applicable) F
Cause of death F
Notes: Main variables categorized as: demographics, diagnostics and results, 
symptoms and clinical observations, prognostic tests and results, follow-up/
treatment, and end of follow-up collected in The Danish National CLL Registry. 
Baseline (B) data are collected at the time of diagnosis and follow-up (F) data are 
collected continuously at the time of significant events, including progression, 
treatment, transplantation, and death. Data of variables included in the IwCLL (I) 
and the CLL-IPI (C) index are collected.
Abbreviations: ID, identification; CLL, chronic lymphocytic leukemia; IWCLL, 
International Prognostic Index for Patients with CLL; CLL-IPI, Chronic Lymphocytic 
Leukemia International Prognostic Index; FISH, fluorescence in situ hybridization; 
IGHV, immunoglobulin heavy chain variable; wHO, world Health Organization; 
MRD, minimal residual disease.
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a completeness of 98%, 96%, 85%, and 55% respectively, 
was achieved. This reflects that despite the cross-referencing 
setup, some lack of time for data entry is seen.
Data from the Danish National CLL registry are made 
publicly available through annual reports,10 which sum-
marize the collected data, including the overall survival 
for yearly cohorts of patients with CLL and the degree of 
data coverage. Also, data for benchmarking of the nine 
hematology centers in Denmark in terms of data coverage 
and outcome for patients treated within the different centers 
are provided. The annual reports form the basis for specific 
queries on missing data to the nine participating centers to 
assure data coverage through engaging local data managers 
at each center.
Examples of research
The growing understanding of the pathogenesis of CLL 
including the dependency on micro environmental interac-
tions and the B-cell receptor pathway has led to a paradigm 
shift in the treatment of patients with CLL.11 This rapid 
develop ment within the translational and clinical research 
area of CLL warrants epidemiological studies of CLL to 
increase knowledge of the outcome for patients with CLL 
treated outside clinical trials. For patients diagnosed with 
CLL in Denmark within 2011–2014, the 3-year overall 
survival rate is 82.9% according to the yearly report.10 
 Currently, pending research issues include but are not 
 limited to: identification of risk factors and genetic factors 
for CLL; addressing the impact of environmental, social, 
and lifestyle conditions as well as the impact of comorbidity 
and treatment-related issues on overall survival over time.12,13 
Some of these questions can be explored solely by using data 
from the Danish National CLL Registry.
In another entity, the Danish Cancer Biobank,14 local 
biobanking of tissue, blood, and bone marrow samples from 
patients diagnosed with cancer are made available for research 
projects upon approval by the local ethics committee system. 
Through a combination of data from the Danish National 
CLL Registry and the Danish Cancer Biobank samples, the 
potential to incorporate laboratory-based functional and 
(epi)genetic analyses for correlation with clinical outcomes 
on a population level can be accomplished.15,16 At an even 
larger scale, international scientific collaborations including 
merging of cohorts provide the leverage to answer strategic 
treatment-related questions as well as to achieve the increased 
power needed to explore rare events and interactions. Also, for 
ongoing and planned clinical trials, the Danish National CLL 
Registry assures easy access to complete long-term follow-up 
data (Figure 2). To this end, the Danish CLL group participates 
in a number of investigator-initiated trials and collaborate with 
both the Nordic CLL group (www.nordic-cll.org), the German 
CLL study group (www.gcllsg.de), and the Hovon Group 
(www.hovon.nl) in order to coordinate clinical trials.
Conclusion
The Danish National CLL Registry is based within the 
 Danish National Hematology Database. The registry covers 
a complete cohort of all patients newly diagnosed with CLL 
in Denmark since 2008. As of July 1, 2015, 3,082 patients 
have been included in the CLL registry. It forms the basis 
for quality assessment of treatment for patients with CLL in 
Denmark, and offers a unique opportunity for population-
based research projects. Through yearly cross-referencing 
with other Danish health-related national registries, high 
quality of data and consistent follow-up is ensured and a 
multitude of research projects that have hitherto not been 
possible, are made feasible.
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